遺伝子隔離物における血圧の変動に関連したアンジオテンシノゲン遺伝子のポリモルフィズム
R A Hegele1, J H Brunt, P W Connelly
1Department of Medicine, St. Michael's Hospital, University of Toronto, Ontario, Canada.
Circulation
|November 1, 1994
まとめ
血管新生素 (AGT) 遺伝子の遺伝的変異は,ハッテライト族の男性における静脈動脈血圧の差異と関連しています. 具体的には,AGTコドン174のポリモルフィズムが,このユニークな集団内の男性における血圧に大きな影響を及ぼします.
科学分野:
- 遺伝学 遺伝学とは
- 心血管生理学 心血管の生理学
- 人口の健康 人口の健康
背景:
- ハッテライト兄弟は,高度な親戚関係と共同生活を送るユニークな遺伝的孤立を代表しています.
- 以前の研究では,アニオテンシノゲン (AGT) とアニオテンシン変換酵素 (ACE) の遺伝子と血圧の変動との間の潜在的な関連が示唆されています.
研究 の 目的:
- AGTとACEの遺伝子ポリモルフィズムとハッテライト集団の静止血圧の関連性を調査する.
- 観察された関連が性に依存しているかどうかを判断する.
主な方法:
- 741人のハッテライトの血圧を4回測定した.
- DNA分析には,ACE挿入/消去 (I/D) ポリモルフィズムとAGT M235TおよびT174Mポリモルフィズムのためのゲノタイプ化が含まれていました.
- 統計テストは,遺伝子型と血圧の変動の関係を評価した.
主要な成果:
- AGTコドン174のゲノタイプは,シストリック血圧の変動と有意な関連性を示した.
- この関連性は男性に特異的であり,性依存的効果を示している.
- AGTコドン174のポリモルフィズムが,男性における全収縮血圧変動の3.1%を説明した.
結論:
- AGT遺伝子変異は,フッテライト族の男性における静止血圧と関連しています.
- この発見は,血圧に影響を及ぼすAGT遺伝子内またはその近くに性特有の機能要素が存在することを示唆しています.
さらに関連する動画
関連する概念動画
01:49Multiple Allele Traits
The Concept of Multiple Allelism
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...